|
There are currently two treatments available in Australia for Fabry Disease. Patients in consultation with their doctor should consider all available information when choosing which enzyme therapy is most appropriate for their needs.
Agalsidase - beta (Fabrazyme®)
Agalsidase - alfa (Replagal®)
Funding for the treatment of Fabry Disease
Due to the rarity of the disease the cost of treatment is proportionately more expensive than other drugs on the Pharmaceutical Benefits Scheme (PBS). Therefore treatment is funded through various government programs such as:
Funding in Australia is provided by the Federal Government in The Life Saving Drugs Program.
Currently there is no funding in New Zealand for Fabry disease, however an application can be made by your doctor to PHARMAC via the Exceptional Circumstances Program.
|
DRUG
|
COST PER VIAL
|
APPROX. COST PER PATIENT PER YEAR*
|
|
FABRAZYME ®
|
5mg
|
$946
|
$313,000 based on 1.0 mg/kg body weight
|
|
35mg
|
$6,024
|
|
|
|
|
|
|
REPLAGAL®
|
3.5mg
|
$2,230
|
$232,000 based on 0.2 mg/kg body weight
|
(*): Based on fortnightly doses for a person weighing 70kg
Criteria and conditions of eligibility
Guidelines for Eligibility to receive treatment with Algalsidase through the Life Saving Drugs Program (129kb)
Application Form for subsidised Enzyme Replacement therapy for Fabry disease (262kb)
Criteria and conditions applying to financial assistance under the Life Saving Drugs Program
These documents are provided as Adobe Acrobat pdf files. You will need to install the Adobe Acrobat reader on your computer to view these files. The Adobe Acrobat Reader is available free of charge from Adobe's website
|
